Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.

This study intends to compare short-term efficacy of 12 chemotherapy regimens in treatment of advanced non-small cell lung cancer (NSCLC) by a network meta-analysis (NMA). PubMed, Cochrane Library, and Embase were searched from the inception of each database to June 2018. Randomized controlled trials (RCTs) of the 12 chemotherapy regimens for advanced NSCLC were included. Direct and indirect evidence were combined by NMA to evaluate the odds ratio and the surface under the cumulative ranking curves (SUCRA) of the 12 chemotherapy regimens. Nineteen RCTs that met our inclusion criteria were collected in this study. For partial response (PR), gemcitabine exhibited relatively poor efficacy compared with cisplatin + gemcitabine, carboplatin + gemcitabine, carboplatin + paclitaxel, paclitaxel + gemcitabine, and cisplatin + gemcitabine + vinorelbine. For overall response rate (ORR), gemcitabine had poorer efficacy than cisplatin + gemcitabine and paclitaxel + gemcitabine. For disease control rate (DCR), compared with carboplatin + gemcitabine and gemcitabine, paclitaxel + gemcitabine had a better efficacy. Gemcitabine had the lowest SUCRA values in terms of complete response, PR, ORR, stable disease, and DCR; whereas paclitaxel + gemcitabine ranked the highest in ORR, progressive disease, and DCR. The cluster analysis revealed that cisplatin + gemcitabine, paclitaxel + gemcitabine, and cisplatin + gemcitabine + vinorelbine had better short-term efficacy for advanced NSCLC. Collectively, short-term efficacy of multidrug combination chemotherapy regimens was superior to that of single-drug chemotherapy regimens for advanced NSCLC. Cisplatin + gemcitabine, paclitaxel + gemcitabine, and cisplatin + gemcitabine + vinorelbine may have particularly prominent short-term efficacy for advanced NSCLC.

[Downregulation of miR-18a or miR-328 inhibits the invasion and migration of lung adenocarcinoma A549 cells].

Objective To investigate the expressions of miR-18a and miR-328 in lung adenocarcinoma A549 cells, and explore the effect of miR-18a or miR-328 on invasion and migration of A549 cells. Methods The expressions of miR-18a and miR-328 in A549 cells were detected by real-time quantitative PCR. Then the specific miR-18a or miR-328 inhibitor sequences were transfected into A549 cells to downregulate the expression of miR-18a or miR-328. The invasion and migration abilities of A549 cells were evaluated by Transwell(TM) assay. Results The miR-18a and miR-328 were overexpressed in A549 cells. And with the corresponding inhibitors being transfected, the expressions of miR-18a and miR-328 in A549 cells were downregulated. In addition, TranswellTM assay showed that decreased expression of miR-18a or miR-328 significantly inhibited the invasion and migration of A549 cells. Conclusion Downregulation of miR-18a or miR-328 can inhibit the invasion and migration abilities of A549 cells effectively.